Overview

Safety and Efficacy Study of High Dose Colistin

Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
0
Participant gender:
All
Summary
Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
King Saud Medical City
Treatments:
Colistin
Criteria
- Inclusion Criteria:

1. Patient age more than or equal 18 years old.

2. Patient has clinical signs and symptoms of infection with suspected or proven
infection due to Carbapenem resistant microorganism.

3. Patient was started with Empirical therapy of Colistin and positive MDRO within 5
days of empirical therapy.

- Exclusion Criteria:

1. Patient age less than 18 years.

2. Pregnant patient.

3. If received Colistin treatment for less than 72 hours.

4. Renal Replacement Therapy.